Financials Intervacc AB

Equities

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 11:29:32 2024-04-26 am EDT 5-day change 1st Jan Change
4.175 SEK +3.34% Intraday chart for Intervacc AB +0.85% -34.04%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 781.4 2,648 2,669 1,313 479.4 316.2 - -
Enterprise Value (EV) 1 729.3 2,485 2,553 1,267 391.2 200.2 261.2 280.2
P/E ratio -25.4 x -97.8 x -90.2 x -20.3 x -3.75 x -4.09 x -4.8 x -9.71 x
Yield - - - - - - - -
Capitalization / Revenue 64.4 x 554 x 509 x 136 x 59.8 x 16.5 x 5.95 x 2.3 x
EV / Revenue 60.1 x 520 x 487 x 131 x 48.8 x 10.4 x 4.92 x 2.04 x
EV / EBITDA -33.6 x -127 x -110 x -29.1 x -5.67 x -3.69 x -6.31 x -73.7 x
EV / FCF -17.5 x -78.9 x -53.3 x -16.7 x -8.16 x -3.23 x -4.28 x -14.7 x
FCF Yield -5.72% -1.27% -1.88% -5.99% -12.3% -31% -23.4% -6.78%
Price to Book 3.55 x 7.84 x 8.66 x 5.25 x 2.01 x 1.23 x 1.62 x 1.87 x
Nbr of stocks (in thousands) 43,293 50,160 50,160 50,491 75,736 75,736 - -
Reference price 2 18.05 52.80 53.20 26.00 6.330 4.175 4.175 4.175
Announcement Date 2/21/20 2/18/21 2/18/22 2/17/23 2/16/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 12.14 4.78 5.241 9.684 8.015 19.2 53.1 137.2
EBITDA 1 -21.69 -19.5 -23.24 -43.56 -68.98 -54.3 -41.4 -3.8
EBIT 1 -27.85 -25.68 -29.39 -64.41 -93.58 -80 -68 -32
Operating Margin -229.41% -537.15% -560.83% -665.15% -1,167.55% -416.67% -128.06% -23.32%
Earnings before Tax (EBT) 1 -27.89 -25.6 -29.38 -64.16 -91.46 -77 -66 -31
Net income 1 -27.89 -25.6 -29.38 -64.16 -102.9 -77 -66 -32
Net margin -229.77% -535.59% -560.48% -662.52% -1,283.24% -401.04% -124.29% -23.32%
EPS 2 -0.7100 -0.5400 -0.5900 -1.280 -1.690 -1.020 -0.8700 -0.4300
Free Cash Flow 1 -41.73 -31.5 -47.9 -75.92 -47.94 -62 -61 -19
FCF margin -343.78% -658.97% -913.95% -783.99% -598.14% -322.92% -114.88% -13.85%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/21/20 2/18/21 2/18/22 2/17/23 2/16/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3
Net sales 1 2.18 - 2.612 2.016
EBITDA 1 - - -9.805 -8.612
EBIT 1 -8.798 - -15.74 -14.58
Operating Margin -403.58% - -602.57% -723.36%
Earnings before Tax (EBT) 1 - - -15.77 -14.62
Net income 1 -8.729 -10.73 -15.77 -14.62
Net margin -400.41% - -603.71% -724.95%
EPS -0.1700 -0.2100 - -
Dividend per Share - - - -
Announcement Date 2/18/22 5/20/22 8/31/22 11/10/22
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 52.1 164 115 45.5 88.2 116 55 36
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -41.7 -31.5 -47.9 -75.9 -47.9 -62 -61 -19
ROE (net income / shareholders' equity) -13.6% -9.19% -9.1% -23% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 5.080 6.730 6.150 4.950 3.140 3.400 2.580 2.230
Cash Flow per Share - -0.4300 - - - - - -
Capex 1 39.1 11.4 22.4 5.25 0.06 - 1 2
Capex / Sales 322% 238.87% 428.11% 54.22% 0.7% - 1.88% 1.46%
Announcement Date 2/21/20 2/18/21 2/18/22 2/17/23 2/16/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. IVACC Stock
  4. Financials Intervacc AB